HTL Hamilton Thorne Ltd

Hamilton Thorne Announces Dr. Thomas Ebner and Cynthia Hudson to Join Its Scientific Advisory Board

Hamilton Thorne Announces Dr. Thomas Ebner and Cynthia Hudson to Join Its Scientific Advisory Board

BEVERLY, Mass. and TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced the strengthening of its Scientific Advisory Board with the appointments of Dr. Thomas Ebner and Cynthia Hudson.

David Wolf, President and CEO of Hamilton Thorne Ltd., commented, “We are pleased to welcome Thomas and Cynthia to our Scientific Advisory Board. They are both accomplished clinicians with invaluable knowledge who will serve as a strategic resource for Hamilton Thorne and provide scientific review and high-level advice about the company’s scientific, product, and commercial initiatives.”

Thomas Ebner, PhD, is an ESHRE-certified Senior Clinical Embryologist (2008) with 25 years of hands-on experience in IVF laboratories. He served as board member of Alpha – Scientists in Reproductive Medicine for 3 years and is currently a member of the Executive Board of ESHRE (2017-2021). Dr. Ebner edited or co-edited two books and has published more than 15 book chapters and 150 papers in national and international peer-reviewed journals. His main scientific interests include culture media, assisted oocyte activation, time-lapse technology, and oocyte competence.

Cynthia Hudson is the Executive Director of Embryology, Strategy, and Operations for TMRW Life Sciences, a company that created the world’s first and only automated platform for the management and storage of cryopreserved fertility tissue. Her experiences in the design and buildout of new fertility practices led her to establish one of the first embryologist-owned-and-operated IVF centers in New York City. She’s launched two licensed medical practices, owns a laboratory consulting company, and is a co-founder of KindBody, the ground-breaking startup that has disrupted the fertility space with novel pricing and woman-centered care. Cynthia holds a Master of Science degree in Clinical Embryology from the University of Leeds in England. She is a member of the American Association of Bioanalysts (AAB), American Society for Reproductive Medicine (ASRM), European Society of Human Reproduction and Embryology (ESHRE), and the American College of Embryology (EMBCOL).

About Hamilton Thorne Ltd. ()

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:
   
David Wolf, President & CEO

Hamilton Thorne Ltd.

978-921-2050

 
Michael Bruns, CFO

Hamilton Thorne Ltd.

978-921-2050

 
Glen Akselrod

Bristol Investor Relations

905-326-1888

 



EN
15/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hamilton Thorne Ltd

 PRESS RELEASE

Hamilton Thorne Announces Shareholder Approval of Going Private Transa...

Hamilton Thorne Announces Shareholder Approval of Going Private Transaction BEVERLY, Mass. and TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd (TSX: HTL) (“Hamilton Thorne” or the “Company”), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies (“ART”), research, and the cell biology fields, today announced that the shareholders of the Company (the "Shareholders"), at a special meeting of Shareholders held earlier today (the "Meeting"), approved a statutory plan of arrangement (the "Transaction") under t...

 PRESS RELEASE

Hamilton Thorne Announces Mailing of Meeting Materials and Receipt of ...

Hamilton Thorne Announces Mailing of Meeting Materials and Receipt of Interim Order in Respect of Going Private Transaction BEVERLY, Mass. and TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd (TSX: HTL) (“Hamilton Thorne” or the “Company”), a leading provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies (“ART”), research, and the cell biology space, today announced the mailing of its notice of meeting, management information circular (the "Circular"), form of proxy and letter of transmittal (collectively, the "Meetin...

 PRESS RELEASE

Hamilton Thorne Reports Revenue for the Quarter and Six Months Ended J...

Hamilton Thorne Reports Revenue for the Quarter and Six Months Ended June 30, 2024, and Confirms Annual Guidance Revenue of $19.1 million and Adjusted EBITDA of $3.2 million for the quarter BEVERLY, Mass. and TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software, and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the quarter and six months ended June 30, 2024. Financial Highlights Sal...

 PRESS RELEASE

Hamilton Thorne to Release Q2 2024 Financial Results on August 14, 202...

Hamilton Thorne to Release Q2 2024 Financial Results on August 14, 2024 BEVERLY, Mass. and TORONTO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and six months ended June 30, 2024 before market open on Wednesday, August 14, 2024. The press release, with accompanying financial information, will be posted on the C...

 PRESS RELEASE

Hamilton Thorne Announces Agreement to be Acquired by Astorg for CAD$2...

Hamilton Thorne Announces Agreement to be Acquired by Astorg for CAD$2.25 Per Share in Cash Purchase price of CAD$2.25 per Hamilton Thorne share represents enterprise value of approximately CAD$388 million (US$282 million).Represents a premium of approximately 54% to the closing price on the Toronto Stock Exchange (“TSX”) of Hamilton Thorne shares on July 19, 2024, the last trading day prior to the announcement of the transaction, and approximately 62% to the 90-day VWAP as of the same date1.The Board of Directors of Hamilton Thorne (with interested directors abstaining) unanimously determi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch